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C-myb and B-myb belong to the myb family of
transcription factors. We have shown previously that
c-myb is deregulated in fibroblasts from systemic
sclerosis (scleroderma) patients relative to normal
fibroblasts. Scleroderma fibroblasts are known to
express elevated levels of collagen genes and trans-
forming growth factor b is known to be a pro-fibrotic
cytokine and to induce transcription of type I collagen
genes. We have therefore investigated the role of c-myb
and B-myb in the regulation of type I collagen genes
in response to transforming growth factor b in normal
human fibroblasts. We show that, in these cells, trans-
forming growth factor b treatment induces c-myb as
well as collagen a1(I) and a2(I) gene expression,
but not B-myb. Furthermore we demonstrate by co-
The v-myb oncogene is responsible for differenttypes of chicken leukemias through deregulation ofhematopoietic cell proliferation and differentiation(Introna et al, 1990; Graf, 1992; Introna et al,1994). In order to understand the molecular
mechanism for myb-induced oncogenesis, great emphasis has
been given to the study of the parental oncogene and of the
three mammalian homologs (A-myb, B-myb, and the proto-
oncogene c-myb) in the context of hematopoietic cells in
different species (Introna et al, 1994; Lipsick, 1996). Nonetheless,
the different members of the myb family have been reported
to be expressed and to function in some other cell types. In
particular, the cell cycle regulated expression of B-myb in
smooth muscle, fibroblasts and diverse hematopoietic cells, as
well as anti-sense studies, have suggested a quite universal role
for B-myb in the control of cell proliferation (Arsura et al,
1992, 1994; Reiss et al, 1991; Lam et al, 1992; Marhamati and
Sonenshein, 1996). C-myb has been shown to render fibroblasts
insulin-like growth factor independent for growth (Travali et al,
1991). Moreover, we have described an abnormal expression of
c-myb gene in scleroderma fibroblasts (Piccinini et al, 1996), a
disease characterized by the excessive deposition of extracellular
matrix constituents (Uitto et al, 1979).
Type I collagen (the most abundant protein in vertebrates) is
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transfection assays that c-myb can upregulate a1(I)
and a2(I) collagen promoters by 6–10-fold whereas B-
myb is inactive. The activity of c-myb on both type I
collagen promoters requires a functional c-myb DNA
binding domain suggesting a direct interaction
between c-myb and these promoters. Indeed c-myb
is active also on a 500 bp fragment of the a2(I)
collagen promoter and can bind to this fragment in
electrophoretic mobility shift assays. Finally, we show
that anti-c-myb anti-sense treatment reduces a1(I) and
to a lesser extent a2(I) collagen gene expression. These
data strongly suggest that c-myb, but not B-myb,
plays a direct role in the upregulation of type I collagen
gene expression in response to transforming growth
factor b. J Invest 112:191–196, 1999
synthesized mostly by two cell types, the fibroblasts and the
osteoblasts (de Crombrugghe et al, 1991; Rossert and Garrett,
1995). It is a heterotrimeric protein composed of two α1(I)
chains and one α2(I) chain that are encoded by two different
genes, the α1(I) and α2(I) collagen genes (de Crombrugghe
et al, 1991; Rossert and Garrett, 1995). Their transcription is
coordinately regulated and is increased in severe fibrotic conditions
(Uitto et al, 1979; Jimenez et al, 1986; Kahari et al, 1987). The
deposition of type I collagen most likely results from transcriptional
activation of collagen genes in response to cytokines (Rossert
and Garrett, 1995). The most widely studied cytokine involved
in collagen deposition is TGF-β (Rossert and Garrett, 1995;
Greenwel et al, 1997).
The fact that all three myb proteins are transcription factors,
our previous observation on the abnormal expression of c-myb
in scleroderma patients (Piccinini et al, 1996), the known cell
cycle regulated expression of B-myb in fibroblasts (Reiss et al,
1991; Lam et al, 1992) and its previously suggested inhibitory
role on α1(I) and α2(I) collagen genes in smooth muscle cells
(Marhamati and Sonenshein, 1996) has led us to investigate
which part the c-myb and B-myb transcription factors played
on type I collagen gene expression in a fibroblast context. In
particular we investigated the effect of transforming growth
factor (TGF) -β1 on myb expression in fibroblasts as this pro-
fibrotic cytokine is known to induce type I collagen synthesis
in these cells. We show that c-myb induction by TGF-β1, but
not B-myb, correlates with α1(I) and α2(I) collagen gene
expression. Furthermore we demonstrate in co-transfection assays,
that c-myb but not B-myb, upregulates the promoter activity
of the same two collagen genes. Finally we show with anti-
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sense experiments that c-myb also upregulates endogenous
collagen gene expression.
MATERIALS AND METHODS
Cells and cell culture Human skin fibroblasts were obtained from skin
biopsies of normal volunteers. Primary explant cultures were established
in Eagle’s minimum essential medium (EMEM) containing 10% fetal
bovine serum, 2 mM glutamine, penicillin (100 U per ml), and streptomycin
(100 µg per ml). Fibroblasts at the fifth subpassage were used for all
experiments. The cells were grown in EMEM containing 10% fetal bovine
serum until confluence, after which the medium was changed to EMEM
containing 0.2% fetal bovine serum for 48 h and TGF-β1 (Amersham, Little
Chalfont, Bucks, U.K.) was then added at the indicated concentrations. Cells
were collected in guanidine isothiocyanate solution 6 h after TGF-β1
stimulation. NIH-3T3 fibroblasts were grown in DMEM supplemented
with 4.5 g glucose per liter, 2 mM glutamine (Gibco Life Technologies,
Paisley, U.K.), 10% fetal bovine serum (Hyclone Laboratories, Logan, UT)
and 50 mg per ml gentamicin.
Anti-sense experiments The oligonucleotides used for the experiments
were 18-mer anti-sense and sense oligonucleotides with the following
sequences: c-myb antisense: dGTGCCGGGGTCTTCGGGC; and c-
myb sense: dGCCCGAAGACCCCGGCAC. These oligonucleotides had
already been used to inhibit c-myb activity (Gewirtz and Calabretta, 1988;
Arsura et al, 1992; Szczylik et al, 1993). Fibroblasts were treated with 60 µg
per ml c-myb anti-sense and sense oligonucleotides at 0 and 7 h. At 24 h
cells were collected in guanidine-isothiocyanate.
RNA isolation and northern blots Total cellular RNA was extracted
using the guanidine isothiocyanate/cesium chloride method (Sambrook et
al., 1989). Fifteen micrograms total RNA were loaded in a 1% agarose-
formaldehyde gel and transferred to nylon membranes (Du Pont, Boston,
MA) by standard blotting procedures. The cDNA for collagen α1(I) (Hf677
clone) and α2(I) (Hf32 clone) were kindly donated by Dr. C.M. Lapie`re
(Laboratoire de Biologie des Tissues Conjonctifs, University of Lie`ge)
(Mayers et al, 1981; Chu et al, 1982). The probes used for the detection
of B-myb and c-myb transcripts have been described previously (Golay
et al, 1991; Majello et al, 1986). They were labeled with 32P-dCTP by
random priming to specific activities of 5 3 108 cpm per µg DNA.
Hybridizations were performed overnight at 60°C in 1 M NaCl, 1%
sodium dodecyl sulfate, 10% dextran sulfate and 100 µg per ml denatured
salmon sperm DNA using 1.2 3 106 cpm per ml of labeled probe. The
filters were washed twice for 10 min at 60°C with 2 3 sodium citrate/
chloride buffer/1% sodium dodecyl sulfate, 15 min with 0.5 3 sodium
citrate/chloride buffer/0.5% sodium dodecyl sulfate and finally twice
at room temperature with a large volume of 0.5 3 sodium citrate/
chloride buffer.
Semiquantitative analysis of RNA by polymerase chain
reaction One microgram total RNA purified on a standard isothiocyan-
ate/cesium chloride gradient was reverse transcribed in 20 µl. Three
microliters of reverse transcribed product were amplified with B-myb, c-
myb and β-actin primers (Golay et al, 1994a). Polymerase chain reaction
was performed in an automated DNA Thermal Cycler (Perkin Elmer) for
22 cycles. Ten microliters of polymerase chain reaction products were run
in a 1.5% ultrapure agarose gel (BRL) and transferred to nylon membranes
by standard Southern blotting procedures. The probes and hybridization
conditions were identical to those described above for northern blots.
Transfections and CAT assays NIH3T3 fibroblasts were transfected
by the calcium phosphate precipitation method. The reporter plasmids
were as follows: the KHK-CAT construct, a gift from Professor J. Lipsick
(Department of Microbiology, SUNY, Stony Brook, NY) containing eight
myb binding sites cloned upstream to the CAT gene (Grasser et al, 1992).
The Col Cat 3.6 construct, containing the rat α1(I) promoter from –
3520 bp followed by 115 bp of the first exon cloned upstream of CAT
gene was kindly donated by Professor G.E. Sonenshein (Department of
Biochemistry, Boston University School of Medicine) (Marhamati and
Sonenshein, 1996). The pAZ1003 construct, containing the mouse α2(I)
promoter from –2000 to 154 bp of the 59 untranslated region driving
CAT gene was kindly donated by Dr. G. Karsenty (Department of
Molecular Genetics, The University of Texas, MD Anderson Cancer
Center, Houston, Texas) (Galera et al, 1996). Col α2–507 was constructed
by inserting the –507 to 154 α2 promoter fragment from pAZ 1003
obtained by HindIII and XbaI digestion into pBLCaT 3 digested with
BamHI and XbaI. Effector plasmids used were the complete human c-myb
or B-myb cDNA cloned into the pSG5 vector (Stratagene) (Arsura et al,
1994). In addition a c-myb mutant carrying a Cys to Ser mutation at
position 130 and shown to be inactive in binding to DNA was used
(Guehmann et al, 1992). Four micrograms effector plasmids was co-
transfected with 5 µg reporter together with 0.2 µg of CMV-β-galactosidase
plasmid. The empty vectors were used to bring the total amount of DNA
to 15 µg for each plate. Protein concentrations were determined with the
Bio-Rad protein assay (Bio-Rad, Richmond, CA). Measurement of β-
galactosidase activity to normalize for transfection efficiency was made
using chlorophenol red-β-D-galactopyranoside (Boehringer) as substrate.
CAT reactions were carried out at 37°C for 3 h using 0.5 µCi of [14C]-
chloramphenicol (Amersham), using a standard phase extraction protocol.
Electrophoretic mobility-shift assay The HindIII–XbaI α2(I) pro-
moter fragment (–507 to 154) was labeled with 32P-dCTP and Klenow
enzyme and purified on polyacrylamide gel. Binding reactions were carried
out using a bacterially derived c-myb protein and 2 µg poly dIdC, as
previously described (Golay et al, 1994b).
Western blots Transfected NIH-3T3 cells were lyzed in cold 10 mM
Tris–HCl pH 7.0, 50 mM NaCl, 30 mM sodium pyrophosphate,
50 mM NaF, 5 mM ZnCl2, 100 mM sodium vanadate, 1% Triton X-100,
1 mM PMSF, 2.5 U per ml pepstatin, 2.5 U per ml leupeptin, 0.15 mM
benzamidine, 2.8 mg per ml aprotinin, vortexed for 30 s and centrifuged
at 4°C and 15000 r.p.m. for 30 min 40 µg cell lysate were run in a 10%
sodium dodecyl sulfate/polyacrylamide gel. The c-myb and B-myb specific
antibodies and binding conditions have been described before (Arsura et al,
1994). Detection was performed using the ECL chemiluminescence system
(Amersham).
RESULTS
a1 and a2 collagen and c-myb are coinduced by TGF-b1 in
normal fibroblasts Sclerodermic patients’ fibroblasts grown in
culture secrete high levels of type I collagen (Jimenez et al, 1986;
Kahari et al, 1987) and we had previously observed that c-myb
expression is elevated in these cells relative to normal fibroblasts
(Piccinini et al, 1996). TGF-β is known to induce type I collagen
synthesis (de Crombrugghe et al, 1991; Rossert and Garrett, 1995).
In order to investigate whether there could be a link between the
myb transcription factors and type I collagen expression, we
therefore measured c-myb, B-myb and α1(I) and α2(I) collagen
gene expression in normal human fibroblasts stimulated in vitro
with different concentrations of TGF-β1. As shown in Fig 1(A),
northern blot analysis showed that in cultured normal fibroblasts,
TGF-β1 induces α1(I) and α2(I) collagen gene expression in a
concentration-dependent manner. A 2–4-fold increase in expression
of both genes could be observed 6 h after addition of optimal
concentrations of TGF-β1 (Fig 1A). We next investigated whether
myb levels were also modulated by TGF-β1. As shown in Fig 1(B)
c-myb RNA levels are induced 7–12-fold by the same dose of
TGF-β1 required to induce the collagen genes (0.1 ng per ml).
On the other hand B-myb expression levels if anything were
decreased at low doses of TGF-β1 (0.1 and 1 ng per ml) and
remained unchanged at 2 ng per ml (Fig 1B). The same results
were obtained using two different donors. Furthermore, an increase
in both α1(I) and α2(I) collagen gene expression and c-myb gene
expression was observed also after stimulation with interleukin 1
(data not shown). These data show that also in normal fibroblasts,
α1(I), α2(I) collagen and c-myb genes can be regulated in parallel.
c-myb, but not B-myb, upregulates the a1(I) and a2(I)
collagen promoters The co-regulation of the type I collagens
with c-myb in normal and scleroderma fibroblasts suggested that
the c-myb transcription factor could be one factor that upregulates
their expression in these cells. We therefore investigated this
possibility in co-transfection assays, using the α1(I) or α2(I) collagen
promoters cloned upstream from the CAT gene and the human
c-myb cDNA driven by the CMV promoter in an expression
vector. As control we also used the human B-myb cDNA cloned
in the same vector. The expression and reporter constructs were
co-transfected in NIH-3T3 fibroblasts and CAT activity was
normalized for transfection efficiency using a myb unresponsive
β-galactosidase construct. As a control, a reporter known to respond
to c-myb was used, the KHK-CAT construct which carries eight
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Figure 1. Co-induction of a1(I) and a2(I) collagen and c-myb by
TGF-b1. Normal human fibroblasts were treated with increasing doses of
TGF-β1 and RNA was extracted 6 h after addition of the cytokine. (A)
α1(I) and α2(I) collagen expression was analyzed by northern blotting.
The photograph of the ethidium bromide stained gel is shown below. (B)
c-myb, B-myb, and β-actin expression were analyzed by semiquantitative
polymerase chain reaction analysis. The blots were hybridized with the
indicated probes. The results are representative of those obtained with two
different donors.
myb binding sites upstream from the CAT reporter gene (Golay
et al, 1994b). As shown in Fig 2(A), both c-myb and B-myb
expression vectors were functional in that both led to expression
of the c-myb and B-myb proteins detectable by western analysis.
Furthermore, both B-myb and c-myb could induce expression of
the control KHK-CAT reporter, B-myb in fact being much more
efficient than c-myb, with an average 30-fold induction for B-myb
and 5-fold induction for c-myb (Fig 2B). The picture was reversed
when the α1(I) and α2(I) collagen reporters were tested. C-myb
was able to transactivate by 8–12-folds both type I collagen
promoters. B-myb, on the other hand, was weak or inactive:
B-myb transactivated the collagen α1(I) promoter by not more
than 4-fold (about half the activity of c-myb) and was essentially
inactive on the α2(I) promoter (Fig 2B); a 1.5–2.5-fold transactiv-
ation can be considered to be background activity as it is observed
with the myb effector constructs on an empty reporter lacking
specific promoter (data not shown). Thus the ability to induce
significantly transcription from both type I collagen promoters was
specific for c-myb.
Transactivation of type I collagen promoters requires the
c-myb DNA binding domain and involves myb binding to
a 500 bp region of the a2(I) collagen promoter We next
wanted to investigate the DNA binding dependency of the trans-
activation by c-myb. For this purpose, we have assayed the ability
of a DNA binding domain mutant of c-myb to transactivate the
α1(I) and α2(I) collagen promoters. As shown in Fig 3, a c-myb
mutant (mut) carrying a point mutation at a crucial Cys residue
Figure 2. C-myb but not B-myb transactivate the a1(I) and a2(I)
collagen promoters. NIH-3T3 fibroblasts were transiently transfected
with either the KHK-CAT, α1 (I), or α2(I) collagen promoter CAT
constructs and either c-myb, B-myb expression vectors or the empty vector.
One microgram CMV-β gal construct was included in all transfections to
normalize for transfection efficiency. Cells were lyzed 48 h after transfection
and analyzed for myb protein expression (A) or CAT activity (B). (A) myb
expression levels was analyzed by western blotting in lysates from NIH-
3T3 cells transfected with either the B-myb or c-myb (1) expression
vectors or empty vector (–). (B) The measured transactivation activities of
full length c-myb and B-myb against the indicated reporters is shown
together with the standard deviations.
Figure 3. Transactivation of a1(I) and a2(I) collagen promoters
requires the c-myb DNA binding domain. NIH-3T3 fibroblasts were
transfected with the α1(I), α2(I) collagen CAT reporters, or with 500 bp
truncated α2(I) collagen promoter fragment (Col α2–507) and either wild-
type c-myb (c-myb wt), a DNA binding defective c-myb point mutant
(c-myb mut) or with B-myb. Transactivation activity was measured after
normalization for transfection efficiency.
within the second repeat forming the DNA binding domain and
shown previously to be unable to bind to specific myb binding
sites on DNA (Guehmann et al, 1992) also lost nearly completely
the type I collagen promoter transactivating activity.
In an initial attempt to delineate the myb responsive region of
the collagen α2(I), we reduced it to about 500 bp. This shorter
promoter (Col α2–507) was found in co-transfection assays to still
respond to c-myb and not B-myb with similar efficiency as the
complete promoter (Fig 3).
These data suggested that c-myb was able to bind to the type I
collagen promoters and thereby upregulate them. We tested this
hypothesis more directly in band shifts experiments, using the
shorter fragment of the α2(I) collagen promoter, which was still
responsive to c-myb. This α2(I) collagen promoter region was
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Figure 4. The –507 a2 collagen promoter fragment binds to c-
myb protein. The α2(I) collagen 500 bp fragment was labeled with 32P
and used in band shift assays using recombinant human c-myb protein
(myb 45) (Ramsay et al, 1991). As control (lane 2), a bacterial extract
lacking c-myb protein was used. In some experiments, binding was
competed with a 1000 3 excess unlabeled (cold) Mim-A oligonucleotide
(containing a strong myb binding site) or with cold Mim-mut
oligonucleotide lacking such a binding site. The complexed and free probe
is indicated on the right with B (bound) or F (free).
labeled and used in band shift assays using a recombinant
C-terminally truncated c-myb protein, previously shown to effici-
ently bind to specific myb binding sites (Howe and Watson, 1991).
As shown in Fig 4 (lanes 1 and 2), a retarded band was observed
in presence of c-myb protein but not in the presence of control
extracts lacking myb protein. Furthermore, the specificity of the
myb DNA interaction was demonstrated in competition assays.
Excess unlabeled mim-A oligonucleotide, which contains a specific
myb binding site, was able to compete with the α2(I) collagen
promoter fragment for myb binding (Fig 4, lane 3), whereas a
mutated oligonucleotide unable to bind to c-myb, did not compete
(Fig 4, lane 4).
We can conclude from these data that: (i) transactivation of type
I collagen promoters by c-myb requires the DNA binding domain
of c-myb; (ii) a 500 bp fragment of the α2(I) collagen is sufficient
for induction of transcription by c-myb; and (iii) c-myb can directly
and specifically bind to the 500 bp α2(I) collagen fragment. These
data suggest that transactivation of the type I collagen promoters
involves c-myb binding to specific myb binding sites.
c-myb anti-sense but not sense oligonucleotides downregul-
ate a(I) gene collagen expression The data presented so far
suggest that c-myb is involved in upregulation of type I collagen
gene expression in fibroblasts. In order to provide still further
evidence that this is indeed the case also for the endogenous genes,
we have tested the ability of c-myb anti-sense oligonucleotides to
downregulate type I collagen expression. Normal fibroblasts were
treated in vitro either with c-myb anti-sense or sense oligonucleot-
ides, lyzed after 24 h of treatment and the extracted RNA was
tested for both α1(I) and α2(I) collagen expression in northern
blots. As shown in Fig 5, treatment with c-myb anti-sense reduced
by 2-fold α1(I) collagen expression relative to sense treatment. The
Figure 5. Anti-sense c-myb inhibits a1(I) and 2(I) collagen
expression. Normal human fibroblasts were treated with either anti-sense
or sense c-myb oligonucleotides and RNA extracted after 24 h. α1(I)
and α2(I) collagen and GAPDH gene expression were analyzed by
northern blotting.
effect on α2(I) collagen was less evident even though some
reduction in presence of c-myb anti-sense could be observed
(Fig 5). Both the ethidium bromide stained gel and hybridization
with GAPDH showed that the effect of c-myb anti-sense treatment
was not due to differences in RNA quantities in the different lanes.
These data strongly suggest that c-myb, but not B-myb, is
directly involved in the upregulation of endogenous type I collagen
gene expression in fibroblasts.
DISCUSSION
On the basis of the previously described elevated expression of
type I collagen genes and of c-myb in scleroderma fibroblasts
(Jimenez et al, 1986; Kahari et al, 1987; Piccinini et al, 1996) and
of the fact that c-myb is a transcription factor (Introna et al, 1994),
we had hypothesized a possible relationship between these two
events. In support of this hypothesis we have now provided the
following evidence: (i) TGF-β1 upregulates α1(I) and α2(I) collagen
as well as c-myb gene expression with the same dose requirement.
On the contrary, the B-myb gene is not induced by TGF-β1. (ii)
C-myb, but not B-myb, can upregulate the complete α1(I) and
α2(I) collagen promoters as well as a shorter 500 bp fragment of
the latter. (iii) Upregulation of the type I collagen promoters by
c-myb requires a functional DNA binding domain. (iv) C-myb
directly binds to the shorter α2(I) collagen fragment in gel shift
assays. (v) C-myb anti-sense treatment of fibroblasts reduces endo-
genous α1(I) and α2(I) collagen expression. We conclude that
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c-myb is involved in the regulation of type I collagen gene
expression, in particular in their regulation by TGF-β and that this
regulation is likely to involve a direct binding to the promoter by
c-myb and subsequent upregulation of transcription induced by
this factor. B-myb on the other hand does not participate in type
I collagen gene expression at least in the cell type and conditions
studied here.
Our report provides direct evidence for the role of c-myb in
upregulating type I collagen promoters. Previously, B-myb has
been shown to downregulate α1(I) and α2(I) promoters in vascular
smooth muscle cells (Marhamati and Sonenshein, 1996). Interes-
tingly, in the same cells, B-myb was also inhibitory on the KHK-
CAT construct (Marhamati and Sonenshein, 1996), whereas we
observed here that B-myb strongly induced KHK-CAT in NIH-
3T3 cells. B-myb therefore has a clear cell type specific activity,
being inhibitory in vascular smooth muscle cells but activating in
NIH-3T3 fibroblasts. Furthermore, the B-myb activity is also
promoter specific as we show in this report that B-myb is a strong
transactivator on the KHK-CAT reporter but is virtually inactive
on both α1(I) and α2(I) collagen promoters. The most important
finding of the present report is that c-myb is a prime positive
regulator of collagen gene expression. This effect appears to be
direct as the DNA binding domain of c-myb is required and the
protein has been shown to be able to bind to a fragment of the
α2(I) collagen promoter. Furthermore, upregulation of type I
collagen gene expression appears to operate also on the endogenous
promoter as suggested by the anti-sense data presented here, at
least as far as the α1(I) gene is concerned. The lack of effect on
the endogenous α2(I) collagen gene with anti-c-myb oligonucleot-
ides may be due to several factors: the relative inefficiency of
oligonucleotides uptake (Arsura et al, 1992), the relative stability
of the α(I) collagen RNA or the contribution of other factors that
regulate α(I) collagen gene expression.
Functional analysis of the regulatory elements in the collagen
genes has been extensively studied (Schmidt et al, 1986; Lichtler
et al, 1989; Ihn et al, 1996; Hasegawa et al, 1997), although the
molecular links between specific extracellular signals and the
overproduction of collagen are far from being understood (van der
Voort et al, 1997; de Crombrugghe et al, 1991). These reports
show an overall similarity between the mouse and the human
promoters, which contain at least four definite regions from –310
to –70 (Hasegawa et al, 1996; Ihn et al, 1996), the three most
proximal ones being apparently regulated by complexes possibly
containing Sp-1 (Greenwel et al, 1997; Ihn et al, 1997), Krox
(Galera et al, 1996), CBF proteins as well as other unidentified
transcription factors, and with an overall role in the control of
basic transcription (Hasegawa et al, 1997; Ihn and Trojanowska,
1997). The most distal region on the contrary, seems to be an
important cis-acting element to confer the TGF-β responsiveness
(Chung et al, 1996) and controversy exists as far as the role of
AP-1 or Sp-1 in its functional regulation (Chung et al, 1996;
Greenwel et al, 1997; Ihn and Trojanowska, 1997). Previously,
some indirect suggestion for a role for c-myb in the cellular
response of hepatic stellate cells to TGF-α had been presented (Lee
et al, 1995). Our data indicate that c-myb is an important regulatory
factor for α1(I) and α2(I) collagen gene expression also during the
response of fibroblasts to TGF-β. Future work will include the
precise definition of the role of specific myb binding sites within
the collagen promoter elements involved in both basal and/or
TGF-β dependent transcription through site-specific mutagenesis.
Our data are also relevant to the understanding of scleroderma
(systemic sclerosis) pathogenesis. Scleroderma skin fibroblasts show
enhanced connective tissue protein and RNA synthesis as well as
abnormal cell growth in some experimental conditions, such as
low serum levels (Uitto et al, 1979; Jimenez et al, 1986; Kahari
et al, 1987; Trojanowska et al, 1988). We had previously shown
that scleroderma fibroblasts show deregulated c-myb expression
(Piccinini et al, 1996). The data presented here show that elevated
c-myb may be one factor leading to elevated matrix protein and
in particular type I collagen gene expression in this disease.
We thank F. and V. De Ceglie for the graphic work. This work was supported by
the Italian Association for Cancer Research (A.I.R.C.) and in part by a grant to
A.G. from the M.U.R.S.T. (40% 1996 and 1997).
REFERENCES
Arsura M, Introna M, Passerini F, Mantovani A, Golay J: B-myb antisense
oligonucleotides inhibit proliferation of human hematopoietic cell lines. Blood
79:2708–2716, 1992
Arsura M, Luchetti MM, Erba E, Golay J, Rambaldi A, Introna M: Dissociation
between p93B-myb and p75c-myb expression during the proliferation and
differentiation of human myeloid cell lines. Blood 83:1778–1790, 1994
Chu ML, Mayers JC, Bernard MP, Ding JF, Ramirez F: Cloning and characterization
of five overlapping cDNAs specific for the human pro-alpha1 collagen chains.
Nucleic Acids Res 10:5925–5933, 1982
Chung K-Y, Agarwal A, Uitto J, Mauviel A: An AP-1 binding sequence is essential
for regulation of the human a2(I) collagen (COOL1A2) promoter activity by
transforming growth factor-β. J Biol Chem 271:3272–3278, 1996
de Crombrugghe B, Vuorio T, Karsenty G, Maity S, Rutheshouser EC, Goldberg
H: Transcriptional control mechanisms for the expression of type I collagen
genes. Ann Rheum Dis 50:872–876, 1991
Galera P, Park R-W, Ducy P, Mattei MG, Karsenty G: c-krox binds to several sites
in the promoter of both mouse type I collagen genes. J Biol Chem 271:21331–
21339, 1996
Gewirtz AM, Calabretta B: A c-myb antisense oligodeoxynucleotide inhibits normal
human hematopoiesis in vitro. Science 242:1303–1306, 1988
Golay J, Capucci A, Arsura M, Castellano M, Rizzo V, Introna M: Expression of
c-myb and B-myb, but not A-myb, correlates with proliferation in human
hematopoietic cells. Blood 77:149–158, 1991
Golay J, Erba E, Bernasconi S, Peri G, Introna M: The A-myb gene is preferentially
expressed in tonsillar CD381, CD39-, sIgM-B lymphocytes and Burkitt’s
lymphoma cell lines. J Immunol 153:543–553, 1994a
Golay J, Loffarelli L, Luppi M, Castellano M, Introna M: The human A-myb protein
is a strong activator of transcription. Oncogene 9:2469–2479, 1994b
Graf T: Myb: a transcriptional activator linking proliferation and differentiation in
hematopoietic cells. Curr Opin Genet Dev 2:249–255, 1992
Grasser FA, LaMontagne K, Whittaker L, Stohr S, Lipsick JS: A highly conserved
cysteine in the v-Myb DNA-binding domain is essential for transformation
and transcriptional trans-activation. Oncogene 7:1005–1009, 1992
Greenwel P, Inagaki Y, Hu W, Walsh M, Ramirez F: Sp1 is required for the early
response of a2(I) collagen to transforming growth factor-β1. J Biol Chem
272:19738–19745, 1997
Guehmann S, Vorbrueggen G, Kalkbrenner F, Moelling K: Reduction of a conserved
Cys is essential for Myb DNA-binding. Nucleic Acids Res 20:2279–2286, 1992
Hasegawa T, Zhou X, Garrett LA, Ruteshouser EC, Maity SN, de Crombrugghe
B: Evidence for three major transcription activation elements in the proximal
mouse proa2(I) collagen promoter. Nucleic Acids Res 24:3253–3260, 1996
Hasegawa T, Takeuchi A, Miyaishi O, Isobe K-I, de Crombrugghe B: Cloning and
characterization of a transcription factor that binds to the proximal promoters
of the two mouse type I collagen genes. J Biol Chem 272:4915–4923, 1997
Howe KM, Watson RJ: Nucleotide preferences in sequence-specific recognition of
DNA by c-myb protein. Nucleic Acids Res 19:3913–3919, 1991
Ihn H, Trojanowska M: Sp3 is a transcriptional activator of the human a2(I) collagen
gene. Nucleic Acids Res 25:3712–3717, 1997
Ihn H, Ohnishi K, Tamaki T, LeRoy EC, Trojanowska M: Transcriptional regulation
of the human a2(I) collagen gene. J Biol Chem 271:26717–26723, 1996
Ihn H, LeRoy EC, Trojanowska M: Oncostatin M stimulates transcription of the
human a2(I) collagen gene via the Sp1/Sp2-binding site. J Biol Chem 272:24666–
24672, 1997
Introna M, Golay J, Frampton J, Nakano T, Ness SA, Graf T: Mutations in v-myb
alter the differentiation of myelomonocytic cells transformed by the oncogene.
Cell 63:1289–1297, 1990
Introna M, Luchetti M, Castellano M, Arsura M, Golay J: The myb oncogene family
of transcription factors: potent regulators of hematopoietic cell proliferation
and differentiation. Semin Cancer Biol 5:113–124, 1994
Jimenez SA, Feldman G, Bashey RI, Bienkowski R, Rosenbloom J: Coordinate
increase in the expression of type I and type III collagen genes in progressive
systemic sclerosis fibroblasts. Biochem J 237:837–843, 1986
Kahari VM, Multimaki P, Vuorio E: Elevated pro alpha 2(I) collagen mRNA levels
in cultured scleroderma fibroblasts result from the increased transcription rate
of the corresponding gene. FEBS Lett 215:331–334, 1987
Lam EW, Robinson C, Watson RJ: Characterization and cell cycle-regulated
expression of mouse B-myb. Oncogene 7:1885–1890, 1992
Lee KS, Buck M, Hougloum K, Chojkier M: Activation of hepatic stellate cells by
TGFa and collagen type I is mediated by oxidative stress through c-myb
expression. J Clin Invest 96:2461–2468, 1995
Lichtler A, Stover ML, Angilly J, Kream B, Rowe DW: Isolation and characterization
of the rat a1(I) collagen promoter. J Biol Chem 264:3072–3077, 1989
Lipsick JS: One billion years of myb. Oncogene 13:223–235, 1996
Majello B, Kenyon LC, Dalla-Favera R: Human c-myb proto-oncogene: Nucleotide
sequence of cDNA and organization of the genomic locus. Proc Natl Acad Sci
USA 83:9636–9640, 1986
Marhamati D, Sonenshein GE: B-myb expression in vascular smooth muscle cells
196 PICCININI ET AL. THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
occurs in a cell cycle dependent fashion and down-regulates promoter activity
of type I collagen genes. J Biol Chem 271:3359–3365, 1996
Mayers JC, Chu ML, Faro SH, Clark YJ, Prockop DJ, Ramirez F: Cloning of a
cDNA for the pro-alpha2 chain of human type I collagen. Proc Natl Acad Sci
USA 74:3516–3520, 1981
Piccinini G, Lucchetti MM, Caniglia ML, Carossino AM, Montroni M, Introna M,
Gabrielli A: c-myb proto-oncogene is expressed by quiescent scleroderma
fibroblasts and,unlike B-myb gene, does not correlate with proliferation. J Invest
Dermatol 106:1281–1286, 1996
Ramsay RG, Ishii S, Gonda TJ: Increase in specific DNA binding by carboxyl
truncation suggests a mechanism for activation of Myb. Oncogene 6:1875–
1879, 1991
Reiss K, Travali S, Calabretta B, Baserga R: Growth regulated expression of B-myb
in fibroblasts and hematopoietic cells. J Cell Physiol 148:338–343, 1991
Rossert JA, Garrett LA: Regulation of type I collagen synthesis. Kidney Int 47:34–
38, 1995
Sambrook J, Fritsch EF, Maniatis T: Molecular cloning. A Laboratory Manual. New
York: Cold Spring Harbor Laboratory Press, 1989, pp. 1–10
Schmidt A, Rossi P, de Crombrugghe B: Transcriptional control of the mouse a2(I)
collagen gene: functional deletion analysis of the promoter and evidence for
cell specific expression. Mol Cell Biol 6:347–354, 1986
Szczylik C, Skorski T, Ku DH, et al: Regulation of proliferation and cytokine
expression of bone marrow fibroblasts: role of c-myb. J Exp Med 178:997–
1005, 1993
Travali S, Reiss K, Ferber A, Petralia S, Mercer WE, Calabretta B, Baserga R:
Constitutively expressed c-myb abrogates the requirement for insulin growth
factor 1 in 3T3 fibroblasts. Mol Cell Biol 11:731–736, 1991
Trojanowska M, Wu LT, LeRoy EC: Elevated expression of c-myc proto-oncogene
in scleroderma fibroblasts. Oncogene 3:477–481, 1988
Uitto J, Bauer EA, Eiser AZ: Scleroderma: increased biosynthesis of triple helical
type I and type III procollagens associated with unaltered expression of
collagenase by skin fibroblasts in culture. J Invest Dermatol 64:921–930, 1979
van der Voort R, Taher TER, Keehnen MJ, Smit L, Groenink M, Pals ST: Paracrine
regulation of germinal center B cell adhesion through the c-met-hepatocyte
growth factor/scatter factor pathway. J Exp Med 16:2121–2131, 1997
